Rachel Kerr

Rachel Kerr

Auto-generated profile, based on publicly available information

Rachel Kerr

Adjuvant Colorectal Cancer Group, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
AGAxel Grothey
Axel Grothey
ASAlberto F. Sobrero
Alberto F. Sobrero
ASAnthony F. Shields
Anthony F. Shields
TYTakayuki Yoshino
Takayuki Yoshino
JPJames Paul
James Paul
TITimothy Iveson
Timothy Iveson
Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures.

1 June 2019 in The Lancet Oncology
Verified
Journal Article
Closed access
CECathy Eng
Cathy Eng
TKTae Won Kim
Tae Won Kim
JBJohanna Bendell
Johanna Bendell
GAGuillem Argilés
Guillem Argilés
NTNiall C Tebbutt
Niall C Tebbutt
RYR Young
R Young

1 November 2016 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
EDEnric Domingo
Enric Domingo
LFLuke Freeman-Mills
Luke Freeman-Mills
EREmily Rayner
Emily Rayner
MGMark Glaire
Mark Glaire
SBSarah Briggs
Sarah Briggs
DCDavid Church
David Church

1 July 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
SDSusan J Dutton
Susan J Dutton
DFDavid R Ferry
David R Ferry
JBJane M Blazeby
Jane M Blazeby
HAHaider Abbas
Haider Abbas
ADAsa Dahle-Smith
Asa Dahle-Smith
RPRussell D Petty
Russell D Petty

14 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
PLPhilip J. Law
Philip J. Law
MTMaria Timofeeva
Maria Timofeeva
Ceres Fernández-RozadillaCeres Fernández-Rozadilla
Ceres Fernández-Rozadilla
PBPeter Broderick
Peter Broderick
JSJames Studd
James Studd
MDMalcolm G. Dunlop
Malcolm G. Dunlop
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that identifies SNPs at 31 new CRC risk loci. We also identify eight independent risk SNPs at the new and previously reported European CRC loci, and a further nine CRC SNPs at loci previously only identified in Asian populations. We use in situ promoter capture Hi-C (CHi-C), gene expression, and in silico annotation methods to identify likely target genes of CRC SNPs. Whilst these new SNP associations implicate target genes that are enriched for known CRC pathways such as Wnt and BMP, they also highlight novel pathways with no prior links to colorectal tumourigenesis. These findings provide further insight into CRC susceptibility and enhance the prospects of applying genetic risk scores to personalised screening and prevention.

1 April 2018 in The Lancet Oncology
Verified
Journal Article
Open access
TITimothy J Iveson
Timothy J Iveson
RKRachel S Kerr
Rachel S Kerr
MSMark P Saunders
Mark P Saunders
JCJim Cassidy
Jim Cassidy
NHNiels Henrik Hollander
Niels Henrik Hollander
JPJames Paul
James Paul
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine. Patients were assigned (1:1) to receive 3 months or 6 months of adjuvant oxaliplatin-containing chemotherapy. The chemotherapy regimens could consist of CAPOX (capecitabine and oxaliplatin) or FOLFOX (bolus and infused fluorouracil with oxaliplatin). The regimen was selected before randomisation in accordance with choices of the patient and treating physician. The primary study endpoint was disease-free survival and the non-inferiority margin was a hazard ratio of 1·13. The primary analysis was done in the intention-to-treat population and safety was assessed in patients who started study treatment. This trial is registered with ISRCTN, number ISRCTN59757862, and follow-up is continuing. 6088 patients underwent randomisation between March 27, 2008, and Nov 29, 2013. The intended treatment was FOLFOX in 1981 patients and CAPOX in 4107 patients. 3044 patients were assigned to 3 month group and 3044 were assigned to 6 month group. Nine patients in the 3 month group and 14 patients in the 6 month group did not consent for their data to be used, leaving 3035 patients in the 3 month group and 3030 patients in the 6 month group for the intention-to-treat analyses. At the cutoff date for analysis, there had been 1482 disease-free survival events, with 740 in the 3 month group and 742 in the 6 month group. 3 year disease-free survival was 76·7% (95% CI 75·1-78·2) for the 3 month group and 77·1% (75·6-78·6) for the 6 month group, giving a hazard ratio of 1·006 (0·909-1·114, test for non-inferiority p=0·012), significantly below the non-inferiority margin. Peripheral neuropathy of grade 2 or worse was more common in the 6 month group (237 [58%] of 409 patients for the subset with safety data) than in the 3 month group (103 [25%] of 420) and was long-lasting and associated with worse quality of life. 1098 serious adverse events were reported (492 reports in the 3 month group and 606 reports in the 6 month group) and 32 treatment-related deaths occurred (16 in each group). In the whole study population, 3 months of oxaliplatin-containing adjuvant chemotherapy was non-inferior to 6 months of the same therapy for patients with high-risk stage II and stage III colorectal cancer and was associated with reduced toxicity and improved quality of life. Despite the fact the study was underpowered, these data suggest that a shorter duration leads to similar survival outcomes with better quality of life and thus might represent a new standard of care. Medical Research Council, Swedish Cancer Society, NETSCC, and Cancer Research UK.